Spectrum Pharmaceuticals, Inc. (SPPI) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET
Company Participants
Michael Grabow - SVP, Corporate Strategy and Operations
Thomas J. Riga - President and CEO
Francois J. Lebel - EVP and CMO
Nora E. Brennan - EVP and CFO
Conference Call Participants
Unidentified Analyst - Jefferies
Ed White - H.C. Wainwright
Reni Benjamin - JMP Securities
William Wood - B. Riley Securities
Prakhar Agarwal - Cantor Fitzgerald
Operator
Good day and thank you for standing by. Welcome to the Spectrum Pharmaceuticals 2Q 2022 Earnings Conference Call. At this time, all participants are in listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions]. Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your speaker today, Michael Grabow, Senior Vice President of Corporate Strategy and Operations. Please go ahead.
Michael Grabow
Thank you, operator. Good morning to everyone. Thank you for joining us today for Spectrum Pharmaceuticals second quarter 2022 financial results conference call. Our second quarter financial results press release was sent out earlier this morning and is available on our website at www.sppirx.com. Joining me on the call today from Spectrum Pharmaceuticals will be Tom Riga, President and CEO; Dr. Francois Lebel, Chief Medical Officer; and Nora Brennan, Chief Financial Officer.
Before we get started, I would like to reference the notice regarding forward-looking statements included in today’s press release. This notice emphasizes the major uncertainties and risks inherent in the forward-looking statements that we will make this morning. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. With that, let me hand the call over to Tom Riga, CEO of Spectrum.
Thomas J. Riga
Good morning and thank you for joining us on the call today. This is a pivotal time for Spectrum as we work towards FDA approvals in the coming months for our late stage assets Poziotinib and eflapegrastim, both of which are under active review with the agency. Since the beginning of the year we have continued to focus on the following three key business objectives; one, gaining FDA approvals and further advancing our two late stage assets; two, reducing our operating cash burn; and three, ensuring we are prepared to successfully launch both products.